探讨重组促红细胞生成素药理作用的评价方法  

Evaluation methods of recombinant human erythropoietin pharmacological action

作　　者：向环英 杨朝令[2] 马增煌 陈云鹏[3] 

机构地区：[1]黄石市临检中心,湖北黄石435000 [2]黄石理工学院医学院 [3]黄石爱康医院

出　　处：《临床血液学杂志（输血与检验）》2012年第5期640-641,643,共3页Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)

摘　　要：目的:探讨重组人促红细胞生成素(rhEPO)对小鼠药理作用的评价方法。方法:煌焦油蓝染色法计数网织红细胞的数量;自动血细胞计数仪分析平均血红蛋白(MCH)的含量。结果:小鼠年龄对结果影响较大,90d以上的小鼠测定结果较稳定;通过比较小鼠肝脏、脾脏及血液的网织红细胞的数量发现,脾脏对红细胞生成素最敏感;红细胞MCH的含量可以间接反应机体内促红细胞生成素的治疗效果。结论:小鼠体内促红细胞生成素的治疗效果可以通过网织红细胞计数和体外MCH的含量来判断。Objective：To explore the evaluation methods of recombinant human erythropoietin pharmacological action for jimpy mice. Method： Reticulocyte quantity was counted with brilliant cresol blue staining method. MCH level was analyzed by blood cell counter. Result：Jimpy mice age had greater impact on the results. The result of a bove 90 days was stable. Comparison of Jimpy mice liver, spleen and blood reticulocyte number, spleen was the most sensitive. MCH could indirectly reflect the therapeutic efficacy of rhEPO. Conclusion：The therapeutic effica- cy of rhEPO could be judged with reticulocyte quantity and MCH.

关 键 词：促红细胞生成素 网织红细胞 煌焦油蓝 平均血红蛋白 

分 类 号：R555[医药卫生—血液循环系统疾病]